DeepMed Research

Sichuan Huiyu Pharmaceutical Co., Ltd.

🇨🇳China

Country: 🇨🇳China

Ownership: Public

Established: 2010-10-12

Employees: 1.3K

Market Cap: -

Website: http://www.huiyupharma.com

Clinical Trials

Human Bioequivalence Study of Liposomal Amphotericin B for Injection

Not Applicable

Not yet recruiting

Conditions: Invasive Fungal Infections
Neutropenic Fever
Visceral Leishmaniasis

Interventions: Drug: Test product (Liposomal amphotericin B for injection, Sichuan Huiyu Pharmaceutical Co., Ltd.)
Drug: Reference product (AmBisome®, Astellas Pharma US Inc.)

First Posted Date: 2025-05-21

Last Posted Date: 2025-05-21

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 42

Registration Number: NCT06983665

Locations: 🇨🇳
Jinan Central Hospital, No.105, Jiefang Road,, Jinan, Shandong, China

Human Bioequivalence Study of Amphotericin B Liposome for Injection

Not Applicable

Recruiting

Conditions: Invasive Fungal Infections
Neutropenic Fever
Visceral Leishmaniasis

First Posted Date: 2025-05-18

Last Posted Date: 2025-05-21

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 42

Registration Number: NCT06977490

Locations: 🇨🇳
Jinan Central Hospital, No.105, Jiefang Road,, Jinan, Shandong, China

Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy Adult

Interventions: Drug: Ferric Carboxymaltose Injection
Drug: Ferric Carboxymaltose Injection [Injectafer®]

First Posted Date: 2025-03-26

Last Posted Date: 2025-05-18

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 84

Registration Number: NCT06895993

Locations: 🇨🇳
Phase I clinical trial unit of the First Hospital of Jilin University, Changchun, Jilin, China

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Drug: T, 260 mg/m2, paclitaxel for injection (albumin-bound)
Drug: R, 260 mg/m2, paclitaxel for injection (albumin bound).

First Posted Date: 2025-01-09

Last Posted Date: 2025-04-10

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 24

Registration Number: NCT06765590

Locations: 🇨🇳
The First Affiliated hospital of Hennan University of Science & Technology, Luoyang, Henan, China

A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation

Phase 1

Recruiting

Conditions: Moderate or Severe Submental Fullness

Interventions: Drug: HY-2003 (10 mg/ml), BELKYRA and placebo
Drug: HY-2003 (5 mg/ml) and placebo

First Posted Date: 2025-01-03

Last Posted Date: 2025-04-10

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 30

Registration Number: NCT06756490

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Phase 1

Recruiting

Conditions: Solid Tumor

Interventions: Drug: Test Product HYP-6589

First Posted Date: 2024-12-02

Last Posted Date: 2024-12-04

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 115

Registration Number: NCT06712680

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Bioequivalence Study of Iron Sucrose Injection in Healthy Participants

Phase 1

Completed

Conditions: Bioequivalency
Safety Issues

Interventions: Drug: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Drug: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)

First Posted Date: 2024-11-05

Last Posted Date: 2025-03-24

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 48

Registration Number: NCT06674486

Locations: 🇨🇳
Henan (Zhengzhou) Zhonghui Cardiovascular Hospital, Zhengzhou, Henan, China

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Efficacy
Tolerability
Safety

Interventions: Drug: Test Product HY07121

First Posted Date: 2024-10-15

Last Posted Date: 2025-01-07

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 258

Registration Number: NCT06639256

Locations: 🇨🇳
Cancer Hospital of Shandong First Medical University, Jinan, China

Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects

Phase 1

Completed

Conditions: Bioequivalency
Safety Issues

Interventions: Drug: Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd) and Iron Sucrose injection (Reference product, Venofer)
Drug: Iron Sucrose injection (Reference product, Venofer) and Iron Sucrose injection (Test product, manufactured by Sichuan Huiyu Pharmaceutical Co., Ltd)

First Posted Date: 2024-10-01

Last Posted Date: 2024-10-08

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 48

Registration Number: NCT06622148

Locations: 🇨🇳
Henan (Zhengzhou) Zhonghui Cardiovascular Hospital, Zhengzhou, Henan, China

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Phase 1

Recruiting

Conditions: Safety
Tolerability
Efficacy

First Posted Date: 2024-02-06

Last Posted Date: 2025-04-02

Lead Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd

Target Recruit Count: 257

Registration Number: NCT06243354

Locations: 🇨🇳
Hunan Provincial Cancer Hospital, Changsha, Hunan, China
🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China
🇨🇳
Shandong Provincial Cancer Hospital, Jinan, Shandong, China

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy